REG - SkinBioTherapeutics - Annual General Meeting 2021 – Change of Venue

SkinbiotherapeuticsAnnouncement

21/12/2021 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211221:nRSU3762Wa&default-theme=true

RNS Number : 3762W  SkinBioTherapeutics PLC  21 December 2021

21 December 2021

 

SkinBioTherapeutics plc

 

 

Annual General Meeting 2021 - Change of Venue

 

SkinBioTherapeutics plc (the "Company") announced its full year audited
results for the year to 30 June 2021 on 30 November 2021, including notice
that the Company's Annual General Meeting ("AGM") would be held at The Core,
Bath Lane, Newcastle Helix, Newcastle upon Tyne, NE4 5TF on 23 December 2021
at 11.00 am.

 

As set out in the notes to the Notice of Annual General Meeting included in
the Annual Report for the year ended 30 June 2021 published on 30 November
2021, shareholders have been asked not to attend the meeting and to appoint
the Chairman of the meeting as their proxy to attend and vote at the meeting.
In respect of the evolving Coronavirus (COVID-19) situation and in accordance
with the Company's articles of association, the Board has resolved that the
venue of the AGM will be moved to 21 College Court, Macclesfield, SK11 8HN.

 

All other details as advised in the Notice of Annual General Meeting remain
the same.

 

-Ends-

For more information please contact:

 SkinBioTherapeutics plc                                 Tel: +44 (0) 161 468 2760

 Stuart J. Ashman, CEO

 Doug Quinn, CFO
 Cenkos Securities Plc (Nominated Adviser & Broker)      Tel: +44 (0) 20 7397 8900

 Giles Balleny, Max Gould (Corporate Finance)

 Michael Johnson, Dale Bellis (Sales)
 Instinctif Partners (financial press)                   Tel: +44 (0) 20 7457 2020

 Melanie Toyne-Sewell / Nathan Billis                    SkinBio@instinctif.com (mailto:SkinBio@instinctif.com)

 

 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Company's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most
advanced of which are cosmetic skincare and food supplements to modulate the
immune system by harnessing the gut-skin axis. In each area
SkinBioTherapeutics plans to exemplify its technology through human studies.
The Company's first product, AsixBiotix-Ps™, a food supplement to address
the symptoms of mild to moderate psoriasis was launched on 29 October - World
Psoriasis Day.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For
more information, visit: www.skinbiotix.com (http://www.skinbiotix.com/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFLFLVFDLLFIL